Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
Ruth Link‐Gelles, Matthew E. Levy, Manjusha Gaglani, Stephanie A. Irving, Melissa S. Stockwell, Kristin Dascomb, Malini B. DeSilva, Sarah E. Reese, I‐Chia Liao, Toan C. Ong, Shaun J. Grannis, Charlene McEvoy, Palak Patel, Nicola P. Klein, Emily Hartmann, Edward Stenehjem, Karthik Natarajan, Allison L. Naleway, Kempapura Murthy, Suchitra Rao, Brian E. Dixon, Anupam B. Kharbanda, Akintunde Akinseye, Monica Dickerson, Ned Lewis, Nancy Grisel, Jungmi Han, Michelle A. Barron, William F. Fadel, Margaret M. Dunne, Kristin Goddard, Julie Arndorfer, Deepika Konatham, Nimish R. Valvi, J. C. Currey, Bruce Fireman, Chandni Raiyani, Ousseny Zerbo, Chantel Sloan-Aagard, Sarah W. Ball, Mark G. Thompson, Mark W. Tenforde
Abstract
.
Topics & Concepts
MedicineCoronavirus disease 2019 (COVID-19)VaccinationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakInternal medicineVirologyPediatricsOutbreakInfectious disease (medical specialty)DiseaseSARS-CoV-2 and COVID-19 ResearchVaccine Coverage and HesitancyCOVID-19 Clinical Research Studies